caa a22 4500 606158618 CHVBK 20210128100620.0 cr unu---uuuuu 210128e20151001xx s 000 0 eng 10.1007/s10557-015-6618-1 doi (NATIONALLICENCE)springer-10.1007/s10557-015-6618-1 Effect of Metformin on Renal Function After Primary Percutaneous Coronary Intervention in Patients Without Diabetes Presenting with ST-elevation Myocardial Infarction: Data from the GIPS-III Trial [Elektronische Daten] [Rene Posma, Chris Lexis, Erik Lipsic, Maarten Nijsten, Kevin Damman, Daan Touw, Dirk van Veldhuisen, Pim van der Harst, Iwan van der Horst] Purpose: The association between metformin use and renal function needs further to be elucidated since data are insufficient whether metformin affects renal function in higher risk populations such as after ST-elevation myocardial infarction (STEMI). Methods: We studied 379 patients included in the GIPS-III trial in which patients without diabetes or renal dysfunction, who underwent primary percutaneous coronary interventions (PCI) for STEMI, were randomized to metformin 500mg or placebo twice daily for four months. At baseline and at seven scheduled visits up to four months after PCI, estimated glomerular filtration rate (eGFR) was determined (2582 values). Contrast-induced acute kidney injury (CI-AKI) was defined as an increase in serum creatinine of ≥0.3mg/dl or 25% rise within 48h after PCI. Results: At all visits, the mean eGFR was similar in patients randomized to metformin or placebo. Over the four month period, mixed-effect repeated-measures model analysis showed a least-squares mean ± standard error change in eGFR of -5.9 ± 0.8ml/min/1.73m2 in the metformin group and −7.1 ± 0.8ml/min/1.73m2 in the control group (P = 0.27 for overall interaction). The incidence of CI-AKI was 14.8%; 29 (15.2%) patients in the metformin group versus 27 (14.4%) controls (P = 0.89). After adjustment for covariates, metformin treatment was not associated with CI-AKI (odds ratio: 0.96, 95%CI 0.52 − 1.75, P = 0.88). Conclusion: We conclude that initiation of metformin shortly after primary PCI has no adverse effect on renal function in patients without diabetes or prior renal impairment, further providing evidence of the safety of metformin use after myocardial infarction and subsequent contrast exposure. The Author(s), 2015 Metformin nationallicence Myocardial infarction nationallicence Renal function nationallicence Acute kidney injury nationallicence Posma Rene Department of Critical Care, University of Groningen, University Medical Center Groningen, Hanzeplein 1, P.O. Box 30.001, 9700 RB, Groningen, The Netherlands aut Lexis Chris Department of Cardiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands aut Lipsic Erik Department of Cardiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands aut Nijsten Maarten Department of Critical Care, University of Groningen, University Medical Center Groningen, Hanzeplein 1, P.O. Box 30.001, 9700 RB, Groningen, The Netherlands aut Damman Kevin Department of Cardiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands aut Touw Daan Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands aut van Veldhuisen Dirk Department of Cardiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands aut van der Harst Pim Department of Cardiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands aut van der Horst Iwan Department of Critical Care, University of Groningen, University Medical Center Groningen, Hanzeplein 1, P.O. Box 30.001, 9700 RB, Groningen, The Netherlands aut Cardiovascular Drugs and Therapy Springer US; http://www.springer-ny.com 29/5(2015-10-01), 451-459 0920-3206 29:5<451 2015 29 10557 https://doi.org/10.1007/s10557-015-6618-1 text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 research-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s10557-015-6618-1 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Posma Rene Department of Critical Care, University of Groningen, University Medical Center Groningen, Hanzeplein 1, P.O. Box 30.001, 9700 RB, Groningen, The Netherlands aut NATIONALLICENCE 700 1- Lexis Chris Department of Cardiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands aut NATIONALLICENCE 700 1- Lipsic Erik Department of Cardiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands aut NATIONALLICENCE 700 1- Nijsten Maarten Department of Critical Care, University of Groningen, University Medical Center Groningen, Hanzeplein 1, P.O. Box 30.001, 9700 RB, Groningen, The Netherlands aut NATIONALLICENCE 700 1- Damman Kevin Department of Cardiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands aut NATIONALLICENCE 700 1- Touw Daan Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands aut NATIONALLICENCE 700 1- van Veldhuisen Dirk Department of Cardiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands aut NATIONALLICENCE 700 1- van der Harst Pim Department of Cardiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands aut NATIONALLICENCE 700 1- van der Horst Iwan Department of Critical Care, University of Groningen, University Medical Center Groningen, Hanzeplein 1, P.O. Box 30.001, 9700 RB, Groningen, The Netherlands aut NATIONALLICENCE 773 0- Cardiovascular Drugs and Therapy Springer US; http://www.springer-ny.com 29/5(2015-10-01), 451-459 0920-3206 29:5<451 2015 29 10557